OncXerna Therapeutics
Waltham
About OncXerna Therapeutics
OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform. OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumor microenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes. The company was founded in 2018 and was formerly known as Oncologie.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $126.5M
- Last round: Series Unknown (Mar 2022)
- Website: oncxerna.com
- Phone: (781) 907 - 7810
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/oncxerna-therapeutics-60686 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.